BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10212131)

  • 1. Novel cyclopropapyrroloindole derivative (AT-3510) bearing methoxycarbonyl and trifluoromethyl groups.
    Fukuda Y; Furuta H; Kusama Y; Ebisu H; Oomori Y; Terashima S
    J Med Chem; 1999 Apr; 42(8):1448-58. PubMed ID: 10212131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel cyclopropapyrroloindole(CPI) bisalkylators bearing methoxycarbonyl and trifluoromethyl groups.
    Fukuda Y; Furuta H; Kusama Y; Ebisu H; Oomori Y; Terashima S
    Bioorg Med Chem Lett; 1998 Jun; 8(11):1387-90. PubMed ID: 9871771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
    Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
    J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
    Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ
    J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological activity of alpha-bromoacryloyl lexitropsin conjugates.
    Romagnoli R; Baraldi PG; Iaconinoto MA; Carrion MD; Tabrizi MA; Gambari R; Borgatti M; Heilmann J
    Eur J Med Chem; 2005 Nov; 40(11):1123-8. PubMed ID: 16006014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy.
    Tietze LF; von Hof JM; Krewer B; Müller M; Major F; Schuster HJ; Schuberth I; Alves F
    ChemMedChem; 2008 Dec; 3(12):1946-55. PubMed ID: 19021160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antitumor activity of CBI-bearing ester and carbamate prodrugs of CC-1065 analogue.
    Wang Y; Li L; Tian Z; Jiang W; Larrick JW
    Bioorg Med Chem; 2006 Dec; 14(23):7854-61. PubMed ID: 16908174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
    Beria I; Baraldi PG; Cozzi P; Caldarelli M; Geroni C; Marchini S; Mongelli N; Romagnoli R
    J Med Chem; 2004 May; 47(10):2611-23. PubMed ID: 15115402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
    Helsby NA; Atwell GJ; Yang S; Palmer BD; Anderson RF; Pullen SM; Ferry DM; Hogg A; Wilson WR; Denny WA
    J Med Chem; 2004 Jun; 47(12):3295-307. PubMed ID: 15163209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2.
    Tsuzuki Y; Tomita K; Shibamori K; Sato Y; Kashimoto S; Chiba K
    J Med Chem; 2004 Apr; 47(8):2097-109. PubMed ID: 15056007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel flavaglines displaying improved cytotoxicity.
    Thuaud F; Ribeiro N; Gaiddon C; Cresteil T; Désaubry L
    J Med Chem; 2011 Jan; 54(1):411-5. PubMed ID: 21142180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
    Jain M; Fan J; Baturay NZ; Kwon CH
    J Med Chem; 2004 Jul; 47(15):3843-52. PubMed ID: 15239662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
    Radi M; Adema AD; Daft JR; Cho JH; Hoebe EK; Alexander LE; Peters GJ; Chu CK
    J Med Chem; 2007 May; 50(9):2249-53. PubMed ID: 17419604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of polyenylpyrrole derivatives as anticancer agents acting through caspases-dependent apoptosis.
    Fang Z; Liao PC; Yang YL; Yang FL; Chen YL; Lam Y; Hua KF; Wu SH
    J Med Chem; 2010 Nov; 53(22):7967-78. PubMed ID: 20964408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.
    Bhide RS; Cai ZW; Zhang YZ; Qian L; Wei D; Barbosa S; Lombardo LJ; Borzilleri RM; Zheng X; Wu LI; Barrish JC; Kim SH; Leavitt K; Mathur A; Leith L; Chao S; Wautlet B; Mortillo S; Jeyaseelan R; Kukral D; Hunt JT; Kamath A; Fura A; Vyas V; Marathe P; D'Arienzo C; Derbin G; Fargnoli J
    J Med Chem; 2006 Apr; 49(7):2143-6. PubMed ID: 16570908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel seco cyclopropa[c]pyrrolo[3,2-e]indole bisalkylators bearing a 3,3'-arylenebisacryloyl group as a linker.
    Fukuda Y; Seto S; Furuta H; Ebisu H; Oomori Y; Terashima S
    J Med Chem; 2001 Apr; 44(9):1396-406. PubMed ID: 11311062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents.
    Lisowski V; Léonce S; Kraus-Berthier L; Sopková-de Oliveira Santos J; Pierré A; Atassi G; Caignard DH; Renard P; Rault S
    J Med Chem; 2004 Mar; 47(6):1448-64. PubMed ID: 14998333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.
    Masterson LA; Spanswick VJ; Hartley JA; Begent RH; Howard PW; Thurston DE
    Bioorg Med Chem Lett; 2006 Jan; 16(2):252-6. PubMed ID: 16290933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
    Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
    Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
    Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
    J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.